BioTelemetry, Inc., a leading provider of remote medical monitoring solutions, is headquartered in the United States. Founded in 1993, the company has established itself as a key player in the healthcare technology industry, focusing on innovative cardiac monitoring and telehealth services. With a strong presence across North America and expanding operations in Europe, BioTelemetry offers unique products such as mobile cardiac telemetry and comprehensive remote patient monitoring systems. The company’s commitment to enhancing patient care through advanced technology has led to significant milestones, including strategic partnerships and acquisitions that bolster its market position. BioTelemetry's core services are distinguished by their reliability and real-time data analytics, making them invaluable for healthcare providers aiming to improve patient outcomes. Recognised for its contributions to the field, BioTelemetry continues to set the standard in remote monitoring solutions.
How does BioTelemetry, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
BioTelemetry, Inc.'s score of 84 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
BioTelemetry, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Koninklijke Philips N.V., which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its corporate family relationship, BioTelemetry, Inc. aligns with the sustainability initiatives and targets set by Koninklijke Philips N.V. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from Koninklijke Philips N.V. at a level 2 relationship. While specific reduction targets or achievements for BioTelemetry, Inc. are not detailed, the overarching commitments from Koninklijke Philips N.V. suggest a focus on reducing carbon emissions and enhancing sustainability practices across its subsidiaries. The absence of direct emissions data indicates that BioTelemetry, Inc. may still be in the process of establishing its own specific climate strategies and targets.
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 449,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 717,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 991,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
BioTelemetry, Inc.'s Scope 3 emissions, which decreased by 8% last year and increased by approximately 361% since 2007, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 55% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
BioTelemetry, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.